Advertisement

Polycystic Ovary Syndrome

  • Joslyn Kirby
Chapter

Abstract

Polycystic ovary syndrome (PCOS) was first described in 1935 by Stein and Leventhal [1]. They described several women with amenorrhea, hirsutism, obesity, and polycystic ovaries. Today, PCOS is one of the most common endocrine diseases in women. It is also one of the most common causes of infertility and menstrual irregularity. Acne is common in women with PCOS and may be the initial reason women with occult PCOS seek medical attention. Inquiring about menstrual irregularity and/or hirsutism in women with acne may facilitate referral to a gynecologist or endocrinologist for early intervention on fertility issues and medical comorbidities.

Keywords

Obstructive Sleep Apnea Polycystic Ovary Polycystic Ovary Syndrome Congenital Adrenal Hyperplasia Menstrual Irregularity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Stein I. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935;29:181.Google Scholar
  2. 2.
    Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83(9):3078–82.PubMedCrossRefGoogle Scholar
  3. 3.
    Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93(1):162–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG. 2006;113(10):1210–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352(12):1223–36.PubMedCrossRefGoogle Scholar
  6. 6.
    Karrer-Voegeli S, Rey F, Reymond MJ, Meuwly JY, Gaillard RC, Gomez F. Androgen dependence of hirsutism, acne, and alopecia in women: retrospective analysis of 228 patients investigated for hyperandrogenism. Medicine (Baltimore). 2009;88(1):32–45.CrossRefGoogle Scholar
  7. 7.
    Walton S, Cunliffe WJ, Keczkes K, et al. Clinical, ultrasound and hormonal markers of androgenicity in acne vulgaris. Br J Dermatol. 1995;133(2):249–53.PubMedCrossRefGoogle Scholar
  8. 8.
    Archer JS, Chang RJ. Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18(5):737–54.PubMedCrossRefGoogle Scholar
  9. 9.
    Falsetti L, Gambera A, Andrico S, Sartori E. Acne and hirsutism in polycystic ovary syndrome: clinical, endocrine-metabolic and ultrasonographic differences. Gynecol Endocrinol. 2002; 16(4):275–84.PubMedGoogle Scholar
  10. 10.
    Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456–88.PubMedCrossRefGoogle Scholar
  11. 11.
    Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–7.Google Scholar
  12. 12.
    Azziz R, Ehrmann D, Legro RS, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001;86(4):1626–32.PubMedCrossRefGoogle Scholar
  13. 13.
    Chuan SS, Chang RJ. Polycystic ovary syndrome and acne. Skin Therapy Lett. 2010; 15(10):1–4.PubMedGoogle Scholar
  14. 14.
    Kelekci KH, Kelekci S, Incki K, Ozdemir O, Yilmaz B. Ovarian morphology and prevalence of polycystic ovary syndrome in reproductive aged women with or without mild acne. Int J Dermatol. 2010;49(7):775–9.PubMedGoogle Scholar
  15. 15.
    Timpatanapong P, Rojanasakul A. Hormonal profiles and prevalence of polycystic ovary syndrome in women with acne. J Dermatol. 1997;24(4):223–9.PubMedGoogle Scholar
  16. 16.
    Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84(1):165–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet. 2003;361(9371):1810–2.PubMedCrossRefGoogle Scholar
  18. 18.
    Talbott E, Guzick D, Clerici A, et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol. 1995;15(7):821–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Gopal M, Duntley S, Uhles M, Attarian H. The role of obesity in the increased prevalence of obstructive sleep apnea syndrome in patients with polycystic ovarian syndrome. Sleep Med. 2002;3(5):401–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Orio Jr F, Palomba S, Spinelli L, et al. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab. 2004;89(8):3696–701.PubMedCrossRefGoogle Scholar
  21. 21.
    Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91(11):4237–45.PubMedCrossRefGoogle Scholar
  22. 22.
    Derksen J, Nagesser SK, Meinders AE, Haak HR, van de Velde CJ. Identification of virilizing adrenal tumors in hirsute women. N Engl J Med. 1994;331(15):968–73.PubMedCrossRefGoogle Scholar
  23. 23.
    Codner E, Villarroel C, Eyzaguirre FC, et al. Polycystic ovarian morphology in postmenarchal adolescents. Fertil Steril. 2011;95(2):702–6. e701-702.PubMedCrossRefGoogle Scholar
  24. 24.
    Azzizz R. The evaluation and management of hirsutism. Obstet Gynecol. 2003;101(5): 995–1007.CrossRefGoogle Scholar
  25. 25.
    Arowojolu AO, Gallo MF, Lopez LM, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2009;3, CD004425.PubMedGoogle Scholar
  26. 26.
    Goodfellow A, Alaghband-Zadeh J, Carter G, et al. Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol. 1984;111(2):209–14.PubMedCrossRefGoogle Scholar
  27. 27.
    Krunic A, Ciurea A, Scheman A. Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone. J Am Acad Dermatol. 2008; 58(1):60–2.PubMedCrossRefGoogle Scholar
  28. 28.
    Yemisci A, Gorgulu A, Piskin S. Effects and side-effects of spironolactone therapy in women with acne. J Eur Acad Dermatol Venereol. 2005;19(2):163–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Cusan L, Dupont A, Gomez JL, Tremblay RR, Labrie F. Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril. 1994; 61(2):281–7.PubMedGoogle Scholar
  30. 30.
    Carmina E, Lobo RA. A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women. Clin Endocrinol (Oxf). 2002;57(2):231–4.CrossRefGoogle Scholar
  31. 31.
    Harborne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2003; 88(9):4116–23.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of DermatologyPenn State HersheyHersheyUSA

Personalised recommendations